Uncategorized
Positive early results seen with iontophoretic EGP-437 in cataract surgery patients
A phase 1b/2a trial of iontophoretic EGP-437 for the treatment of ocular inflammation and pain in post-surgical cataract patients has shown positive results, EyeGate Pharmaceuticals announced in a press release.The multicenter, open-label trial included 30 patients who had undergone cataract surgery with implantation of a posterior chamber IOL. Subjects received EGP-437 at 4.5 mA-min or 14 mA-min or a placebo at 14 mA-min.